|Over a month ago|
Joint Corp. price target raised to $128 from $65 at DA Davidson » 07:5708/0908/09/21
DA Davidson analyst Linda…
DA Davidson analyst Linda Bolton Weiser raised the firm's price target on Joint Corp. to $128 from $65 and keeps a Buy rating on the shares. The analyst cites the company's better than expected Q2 results as system-wide comp sales jumped 53% and also believes that its raised 2021 guidance "still looks conservative" as new patient acquisition volumes hit record levels.
Joint Corp. price target raised to $125 from $105 at B. Riley » 09:1108/0608/06/21
B. Riley analyst Jeff Van…
B. Riley analyst Jeff Van Sinderen raised the firm's price target on Joint Corp. to $125 from $105 and reiterates a Buy rating on the shares post the Q2 results. Enhanced marketing programs contributed to driving momentum in new patient counts and similar activity is expected to continue, Van Sinderen tells investors in a research note.
Joint Corp. price target raised to $150 from $70 at Lake Street » 08:0408/0608/06/21
Lake Street analyst…
Lake Street analyst Brooks O'Neil raised the firm's price target on Joint Corp. to $150 from $70 and keeps a Buy rating on the shares after the company delivered "exceptional" Q2 results and increased FY21 guidance for revenue and AEBITDA. Though he believe the Joint is "sticking to their playbook of being conservative," he believes the company is "firing on all cylinders" and he expects outsized growth over the coming years to precede "significant profitability," O'Neil tells investors.
Joint Corp. reports Q2 EPS 18c, consensus 5c » 16:5208/0508/05/21
Reports Q2 revenue…
Reports Q2 revenue $20.2M, consensus $17.75M. Reported Q2 Reported system-wide comp sales2 of 53%. Reported Q2 Reported system-wide comp sales2 of 53%. "Our business model continues to deliver strong financial results," said Peter D. Holt, President and Chief Executive Officer of The Joint Corp. "In the second quarter, we broke records in franchise license sales, clinic openings, and system-wide sales driving all-time highs for the first half of the year. The six-month total for franchise license sales rose to 89, up from 35 and 75 for 2020 and 2019, respectively. The clinic openings for the first six months of the year increased to 54, up from 30 and 29 in 2020 and 2019, respectively. Additionally, system-wide sales reached 64% year-over-year, up from 2% and 34% in the second quarters of 2020 and 2019, respectively."
Joint Corp. price target raised to $105 from $65 at B. Riley » 07:4908/0308/03/21
B. Riley analyst Jeff Van…
B. Riley analyst Jeff Van Sinderen raised the firm's price target on Joint Corp. to $105 from $65 and reiterates a Buy rating on the shares ahead of the company's Q2 results on August 5. The results have the potential to exceed expectations as clinic visitation rate has continued to increase during the recovery from Covid, Van Sinderen tells investors in a research note. He believes the 53 clinics added since the end of Q2 2020 "ramped up quickly."
Joint Corp. price target raised to $100 from $61 at Craig-Hallum » 09:0607/2907/29/21
Craig-Hallum analyst Jeremy Hamblin raised the firm's price target on Joint Corp. to $100 from $61 and keeps a Buy rating on the shares. The analyst expects Joint Corp. to post strong Q2 results, marked by better-than-expected unit growth in the first half of 2021 and likely upside to revenue. Hamblin believes Joint Corp. has continued to attract new customers at an impressive rate, which sets the stage for clinic productivity to continue growing as the company pushes toward its goal of 1,000-plus clinics by the end of 2023. He sees potential for a full year 2021 guidance raise particularly on higher unit growth, which he believes is tracking above his expectations and is expected to be back half weighted.
Joint Corp. selected by Army & Air Force Exchange Service for chiropractic care » 08:5107/2907/29/21
Joint Corp. has reached…
Joint Corp. has reached an agreement with the Army & Air Force Exchange Service to provide on-installation chiropractic care to members of the military and their families. The initial target sites include Luke Air Force Base in Phoenix, Ariz., MacDill Air Force base in Tampa, Fla. and Joint Base McGuire-Dix-Lakehurst in Trenton, New Jersey. The Exchange operates more than 4,900 facilities in more than 30 countries, 50 states, four U.S. territories and the District of Columbia and serves an eligible customer base of 33 million active-duty and retired service members and their families.
Joint Corp. price target raised to $100 from $65 at Roth Capital » 07:0206/2806/28/21
Roth Capital analyst…
Roth Capital analyst George Kelly raised the firm's price target on Joint Corp. to $100 from $65 and keeps a Buy rating on the shares after taking over coverage of the name. Joint is positioned to grow and take share in the $16B chiropractic industry, Kelly tells investors in a research note. The analyst believes the company's "novel" offering and franchise business model "stand out among industry peers." He sees potential for "sustained rapid growth for years to come" and believes long-term investors "will be handsomely rewarded."
|Over a quarter ago|
Joint Corp. director Amos sells 54,000 common shares » 19:0206/0306/03/21
In a regulatory filing,…
In a regulatory filing, Joint Corp. director James Amos disclosed the sale of 54,000 common shares of the company on June 2 at a price of $71.9987 per share.
Joint Corp. downgraded to Hold at Maxim on valuation » 08:0606/0306/03/21
As previously reported,…
As previously reported, Maxim analyst Anthony Vendetti downgraded Joint Corp. to Hold from Buy. The analyst notes that while the company's fundamentals and growth prospects remain strong, he believes that after a 425% rally in the stock from its 52-week low and over 170% thus far in 2021, the upside has been "priced in". Vendetti adds that Joint Corp's plan to significantly accelerate clinic expansion should put near-term pressure on EBITDA margins.